Loading…
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $67M | $-468M | $-438M | $-397M | -57.2% | 4.4% | -16.1% |
| 2024 | $64M | $-538M | $-522M | $-454M | -45.4% | 61.3% | -15.1% |
| 2023 | $39M | $-651M | $-615M | $-800M | -38.7% | -97.5% | -219.2% |
| 2022 | $1.6B | $840M | $516M | $1.6B | 24.8% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 1,580.47 | 39.49 | 63.71 | 66.52 |
| Cost Of Revenue | 146.32 | 2.76 | 0.84 | 0.03 |
| Gross Profit | 1,434.15 | 36.73 | 62.87 | 66.49 |
| Operating Expense | 601.08 | 707.48 | 615.04 | 546 |
| Operating Income | 833.07 | -670.75 | -552.17 | -479.51 |
| EBITDA | 839.85 | -651.29 | -537.61 | -467.83 |
| EBIT | 833.07 | -670.75 | -552.17 | -479.51 |
| Pretax Income | 754.28 | -628.19 | -523.10 | -437.77 |
| Tax Provision | 238.44 | -13.08 | -1.14 | 0.22 |
| Net Income | 515.84 | -615.06 | -521.96 | -437.99 |
| Net Income Common Stockholders | 515.84 | -615.06 | -521.96 | -437.99 |
| Total Expenses | 747.40 | 710.24 | 615.88 | 546.03 |
| Interest Income | 28.09 | 86.99 | 71.81 | 40.24 |
| Research And Development | 474.65 | 579.72 | 506.50 | 455.97 |
| Selling General And Administration | 161.76 | 174.44 | 119.03 | 92.07 |
| Normalized EBITDA | 950.99 | -615.85 | -497.09 | -469.74 |
| Normalized Income | 591.86 | -580.36 | -481.52 | -439.50 |
| Market Cap | 1,672 | 1,672 | 1,672 | 1,672 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Vir Biotechnology, Inc.this co. | VIR | - | -3.82 | 2.18 | -57.2% | -3.29 |
| Actuate Therapeutics, Inc. Common stock | ACTU | $68M | - | 8.45 | -280.5% | - |
| LENSAR, Inc. | LNSR | $65M | - | -2.48 | 131.7% | -3.17 |
| Pulmonx Corporation | LUNG | $51M | - | 0.92 | -99.8% | -0.71 |
| Accuray Incorporated | ARAY | $50M | - |
| 0.94 |
| -2.0% |
| -107.66 |
| INmune Bio Inc. | INMB | $35M | - | 1.50 | -195.3% | -0.38 |
| Myomo, Inc. | MYO | $31M | - | 2.68 | -136.6% | -2.33 |
| Tvardi Therapeutics, Inc. | TVRD | $29M | - | 1.37 | -87.0% | 0.07 |
| Tevogen Bio Holdings Inc. | TVGN | $27M | - | -1.52 | 319.1% | -1.64 |
| Peer Median | - | - | 1.15 | -93.4% | -1.64 | |